Smith B R
Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut.
Yale J Biol Med. 1990 Sep-Oct;63(5):371-80.
Normal hematopoiesis is a well-regulated process in which the generation of mature blood elements occurs from a primitive pluripotent stem cell in an ordered sequence of maturation and proliferation. Regulation occurs at the level of the structured microenvironment (stroma), via cell-cell interactions and by way of the generation of specific hormones and cytokines: erythropoietin, interleukin 3, granulocyte-monocyte colony-stimulating factor (GM-CSF), monocyte-macrophage colony-stimulating factor (M-CSF), granulocyte colony-stimulating factor (G-CSF), interleukin 5, interleukin 4, and other less well-defined factors, including the megakaryocyte growth factors. Understanding of this complex process has revealed insights into the pathophysiology of human disease and provided a theoretical framework for the therapeutic use of bone marrow transplantation and potential gene transfer therapy. Furthermore, ongoing clinical trials suggest that the hematopoietic growth factors may represent a significant new group of therapeutic reagents for patients with hematological and oncologic disease.
正常造血是一个受到良好调控的过程,在这个过程中,成熟血细胞从原始多能干细胞开始,按照成熟和增殖的有序序列生成。调控发生在结构化微环境(基质)层面,通过细胞间相互作用以及特定激素和细胞因子的产生来实现,这些激素和细胞因子包括促红细胞生成素、白细胞介素3、粒细胞 - 单核细胞集落刺激因子(GM - CSF)、单核细胞 - 巨噬细胞集落刺激因子(M - CSF)、粒细胞集落刺激因子(G - CSF)、白细胞介素5、白细胞介素4以及其他定义不太明确的因子,包括巨核细胞生长因子。对这一复杂过程的理解为人类疾病的病理生理学提供了深刻见解,并为骨髓移植的治疗应用和潜在的基因转移治疗提供了理论框架。此外,正在进行的临床试验表明,造血生长因子可能代表了一类用于治疗血液学和肿瘤疾病患者的重要新型治疗试剂。